<DOC>
	<DOCNO>NCT01052194</DOCNO>
	<brief_summary>This study design evaluate safety assess initial efficacy VX-509 , JAK3 inhibitor , treatment subject active RA . This study assess clinical response 4 dose VX-509 compare placebo administer 12 week patient active RA . The study also evaluate safety tolerability VX-509 compare placebo administer 12 week subject active RA .</brief_summary>
	<brief_title>A 12-week Study 4 Doses VX-509 Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>All subject must diagnose RA define ACR revise criterion disease duration least 6 month confirm diagnosis Subjects must swell joint count ≥6 28 joint tender joint count ≥6 28 joint . Joints prior surgery exclude joint count . Baseline CRP level must 1.5 time great upper limit normal Screening . Subjects must fail least 1 nonbiologic DMARD reason . Subjects may previously fail 1 biologic DMARD discontinue treatment reason inadequate response . Subjects must treat Rituximab previously . Subjects must willing comply contraception requirement . Subjects inflammatory rheumatological disorder RA . History evidence clinically significant disorder RA ( include limit cardiopulmonary , oncologic , renal , metabolic , hematologic psychiatric disorder ) , condition disease , opinion investigator medical monitor , would pose risk subject safety interfere study evaluation , procedure , completion . Subjects clinically important abnormality screen physical examination screen laboratory test result ( include presence either hepatitis B surface antigen , hepatitis C virus antibody , HIV type 1 Subjects elevation alanine aminotransferase aspartate aminotransferase upper limit normal . History hematologic disorder include neutropenia thrombocytopenia . Subjects acute chronic active infection require systemic antimicrobial treatment , subject high risk develop infection due compromise immune system . Antifungals onychomycosis lowdose antibiotic rosacea , inhibitor inducer CYP3A , allow . Subjects require concomitant use inhibitor inducer cytochrome P450 ( CYP ) 3A . Subjects treat intraarticular injection corticosteroid within 28 day prior Day 1 . Subjects plan major surgery ( e.g. , joint replacement ) procedures study . Have receive live , attenuated vaccination within 1 month prior study drug administration . History drug alcohol abuse excessive alcohol determine investigator , last 12 month screen visit . History TB infection kind ( pulmonary extrapulmonary , active latent ) , regardless history antiTB treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>